However,
because the alert would not have been actionable,
because the magnitude of increased risk did not rise
to the predefined level of concern, this effectively
would have been a false positive. In Scenarios D
and E, we can also conclude that the new drug is
no less safe than the comparator because the upper
bound of the CI is below the safety threshold. In
Scenario E, the upper bound is also below the null,
so we could interpret this to indicate that the new drug is safer than the comparator with respect to the null threshold. We could also consider using another
threshold to the left of the null threshold for determining whether the new drug is meaningfully safer than the comparator. Scenario F is one in which no safety statement can be made and in which continued monitoring is warranted.